New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 24, 2012
07:38 EDTARIAARIAD announces FDA acceptance of NDA filing for Ponatinib
ARIAD Pharmaceuticals announced that the FDA has accepted for filing the New Drug Application for accelerated review of ARIADís investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia or Philadelphia-chromosome positive acute lymphoblastic leukemia. The FDA also has granted ARIADís request for Priority Review, which is given to investigational medicines that have the potential for providing significant improvement in the treatment, prevention, or diagnosis of a disease. The FDA has established an action date of March 27, 2013 under the Prescription Drug User Fee Act.
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 10, 2014
12:11 EDTARIAOptions with increasing implied volatility
Subscribe for More Information
09:00 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
07:46 EDTARIAARIAD announces PRAC of EMA recommends Iclusig for continued EU use
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use